Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21659250 | 0.85 | SCN9A (0.51) | RETGPR119HTTSCN9AALDH1A1 | |
| SCHEMBL710593 | 0.83 | GPR119 (0.53) | RETGPR119HTTNR1H2NR1H3 | |
| SCHEMBL8440072 | 0.81 | GPR119 (0.44) | RETGPR119HTTNR1H2NR1H3 | |
| SCHEMBL8431903 | 0.79 | ALDH1A1 (0.56) | RETALDH1A1 | |
| SCHEMBL21659671 | 0.78 | GPR119 (0.53) | RETGPR119HTTALDH1A1MAPT | |
| SCHEMBL22505342 | 0.77 | GPR119 (0.46) | GPR119HTTNR1H2NR1H3ALDH1A1 | |
| SCHEMBL21659579 | 0.77 | ALK (0.49) | GPR119HTTSCN9AALDH1A1MAPT | |
| SCHEMBL31437076 | 0.77 | GPR119 (0.46) | GPR119HTTNR1H2NR1H3ALDH1A1 | |
| SCHEMBL21659246 | 0.77 | HTT (0.43) | RETGPR119HTTSCN9AALDH1A1 | |
| SCHEMBL17432218 | 0.76 | GPR119 (0.51) | RETGPR119HTTSCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | RET 624/4885GPR119 223/4885HTT 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.